CBLL
CeriBell, Inc. NASDAQ Listed Oct 11, 2024$18.18
+0.83%
vs $18.03
Mkt Cap $664.3M
52w Low $10.92
58.0% of range
52w High $23.43
50d MA $19.01
200d MA $17.52
P/E (TTM)
-11.2x
EV/EBITDA
—
P/B
4.3x
Debt/Equity
0.1x
ROE
-34.4%
P/FCF
-16.0x
RSI (14)
54.80
ATR (14)
$0.80
Beta
0.93
50d MA
$19.01
200d MA
$17.52
Avg Volume
348.2K
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
CIK (SEC)
Phone
800 436 0826
360 North Pastoria Avenue · Sunnyvale, CA 94085 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -0.43 | -0.36 | +16.3% | 19.90 | -5.4% | -4.8% | +2.3% | -3.7% | -2.7% | -3.4% | — |
| Nov 4, 2025 | AMC | -0.43 | -0.37 | +14.0% | 10.92 | +3.0% | +7.9% | -1.9% | +3.6% | -1.7% | +6.3% | — |
| Aug 5, 2025 | AMC | -0.40 | -0.38 | +5.0% | 15.08 | -0.5% | -15.3% | -1.6% | +2.6% | -6.1% | -3.5% | — |
| May 8, 2025 | AMC | -0.43 | -0.36 | +16.3% | 17.10 | +4.0% | -6.6% | +7.5% | -3.3% | -0.8% | +6.9% | — |
| Feb 25, 2025 | AMC | -0.32 | -0.40 | -25.0% | 25.54 | -0.5% | -1.3% | -5.7% | -2.2% | +5.9% | -3.5% | — |
| Nov 12, 2024 | AMC | -0.82 | -1.85 | -125.6% | 28.85 | +0.5% | -3.4% | -1.2% | -3.7% | -5.8% | +2.3% | — |
| Oct 11, 2024 | AMC | — | -1.59 | — | 25.00 | +1.2% | +2.0% | +0.1% | +3.5% | +0.3% | +0.6% | — |
| Mar 31, 2024 | AMC | — | -1.59 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.35 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.30 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -1.35 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -1.35 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 28 | BTIG | Maintains | Buy → Buy | — | $21.89 | $21.88 | -0.0% | -6.1% | -0.6% | +0.9% | -1.9% | +1.3% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $21.99 | $22.16 | +0.8% | -1.8% | -1.1% | -0.7% | -0.5% | +0.9% |
| Dec 15 | BTIG | Maintains | Buy → Buy | — | $20.93 | $21.20 | +1.3% | +4.6% | +0.4% | -1.8% | -1.1% | -0.7% |
| Nov 5 | JP Morgan | Maintains | Overweight → Overweight | — | $10.92 | $11.25 | +3.0% | +7.9% | -1.9% | +3.6% | -1.7% | +6.3% |
| Nov 5 | TD Cowen | Maintains | Buy → Buy | — | $10.92 | $11.25 | +3.0% | +7.9% | -1.9% | +3.6% | -1.7% | +6.3% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $25.54 | $25.40 | -0.5% | -1.3% | -5.7% | -2.2% | +5.9% | -3.5% |
| Dec 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $30.24 | $30.89 | +2.1% | -0.7% | -1.4% | -0.1% | -1.4% | +0.1% |
| Dec 9 | TD Cowen | Maintains | Buy → Buy | — | $30.24 | $30.89 | +2.1% | -0.7% | -1.4% | -0.1% | -1.4% | +0.1% |
| Nov 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $28.85 | $29.00 | +0.5% | -3.4% | -1.2% | -3.7% | -5.8% | +2.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Taylor Joseph Michael | — | Sell | 5,500 | $18.41 | $101K | 61,573 | -3.60% | — |
| Jun 8, 2026 | Chao Xingjuan | President and CEO | Sell | 23,554 | $18.33 | $432K | 816,317 | -1.25% | -3.57% |
| Jun 8, 2026 | Chao Xingjuan | President and CEO | Sell | 1,446 | $18.33 | $27K | 816,317 | -1.25% | -3.57% |
| Jun 8, 2026 | Chao Xingjuan | President and CEO | Sell | 14,000 | $18.33 | $257K | 816,317 | -1.25% | -3.57% |
| May 22, 2026 | Foehr David | Senior VP, Finance and PAO | Sell | 862 | $18.80 | $16K | 37,751 | -0.53% | -0.62% |
| May 21, 2026 | Foehr David | Senior VP, Finance and PAO | Sell | 987 | $18.00 | $18K | 38,613 | -0.53% | -0.62% |
| May 21, 2026 | Manni Joseph S. | Chief Revenue Officer | Sell | 1,378 | $18.00 | $25K | 56,291 | -0.53% | -0.62% |
| May 21, 2026 | Blumberg Scott | Chief Financial Officer | Sell | 1,387 | $18.00 | $25K | 147,683 | -0.53% | -0.62% |
| May 21, 2026 | Chao Xingjuan | President and CEO | Sell | 6,030 | $18.00 | $109K | 830,317 | -0.53% | -0.62% |
| May 21, 2026 | Woo Raymond | Chief Technology Officer | Sell | 1,966 | $18.00 | $35K | 195,682 | -0.53% | -0.62% |
| May 5, 2026 | Chao Xingjuan | President and CEO | Sell | 23,554 | $20.09 | $473K | 836,347 | -0.88% | -8.10% |
| May 5, 2026 | Chao Xingjuan | President and CEO | Sell | 1,446 | $20.12 | $29K | 836,347 | -0.88% | -8.10% |
| May 5, 2026 | Chao Xingjuan | President and CEO | Sell | 14,000 | $20.12 | $282K | 836,347 | -0.88% | -8.10% |
| May 1, 2026 | Woo Raymond | Chief Technology Officer | Sell | 6,611 | $20.45 | $135K | 197,648 | +0.49% | -0.69% |
| May 1, 2026 | Woo Raymond | Chief Technology Officer | Sell | 3,024 | $20.43 | $62K | 197,648 | +0.49% | -0.69% |
| May 1, 2026 | Woo Raymond | Chief Technology Officer | Sell | 1,469 | $20.39 | $30K | 197,648 | +0.49% | -0.69% |
8-K · 2.02
!! High
CeriBell, Inc. -- 8-K 2.02: Earnings Results
CeriBell reported Q1 2026 financial results, providing investors with updated performance metrics on revenue, profitability, and operational efficiency for the quarter ending March 31, 2026.
May 11
8-K
CeriBell, Inc. -- 8-K Filing
Ceribell reported full-year 2025 financial results, indicating continued operations in its neurological diagnostic medical device business, though specific revenue or profitability metrics require detailed review.
Feb 24
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 13
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | BNY Mellon Small/Mid Cap Growth Fund | 428,851 | $8M | Mar 2026 |
| 2 | AST Small-Cap Equity Portfolio | 165,000 | $4M | Dec 2025 |
| 3 | F/m Emerald Life Sciences Innovation ETF | 87,031 | $2M | Feb 2026 |
| 4 | Empower Small Cap Growth Fund | 66,470 | $1M | Mar 2026 |
| 5 | BNY Mellon Small Cap Value Fund | 63,836 | $1M | Mar 2026 |
| 6 | BNY Mellon Small Cap Multi-Strategy Fund | 58,757 | $1M | Feb 2026 |
| 7 | SMALL CAP EQUITY FUND | 50,016 | $917K | Mar 2026 |
| 8 | AMG TimesSquare Small Cap Growth Fund | 38,587 | $707K | Mar 2026 |
| 9 | Small Cap Index Fund | 13,142 | $241K | Mar 2026 |
| 10 | Avantis U.S. Small Cap Equity ETF | 11,371 | $212K | Feb 2026 |
| 11 | Penn Series Small Cap Index Fund | 800 | $15K | Mar 2026 |
| 12 | Russell 2000 Fund | 58 | $1K | Mar 2026 |
| 13 | Russell 2000 1.5x Strategy Fund | 35 | $642 | Mar 2026 |
Valuation
Market Cap
$664.3M
Enterprise Value
$524.9M
P/E (TTM)
-11.15x
Forward P/E
—
PEG Ratio
0.26x
P/B
4.28x
P/S
6.99x
P/FCF
-15.98x
EV/EBITDA
—
Shares Out
36.5M
Financials (TTM)
Revenue
$95.1M
Net Income
-$60.4M
EBITDA
-$57.3M
Free Cash Flow
-$41.6M
Op Cash Flow
-$40.8M
EPS Basic
$-1.46
EPS Diluted
$-1.63
EPS Forward
$-1.46
Gross Margin
87.7%
Op Margin
-68.3%
Net Margin
-63.5%
Balance Sheet
Total Assets
$195.8M
Total Liab.
$40.5M
Total Equity
$155.3M
Cash
$159.3M
LT Debt
$19.8M
Book Value/Sh
$4.25
Debt/Equity
0.14x
Current Ratio
9.73
Quick Ratio
9.35
Returns & Growth
ROE
-34.4%
ROA
-27.3%
ROIC
-32.9%
Rev Growth YoY
+36.1%
EPS Growth YoY
+56.9%
Price Returns
2W
+12.1%
1M
-8.5%
3M
-1.2%
6M
+8.7%
12M
+9.8%
Technicals
52W High
$23.43
52W Low
$10.92
50d MA
$19.01
200d MA
$17.52
RSI (14)
54.80
ATR (14)
$0.80
Beta
0.93
Avg Volume
348K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$30.00
High
$30.00
Low
$30.00
Median
$30.00
Data updated apr 25, 2026 12:05am
· Source: financialmodelingprep.com